Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Aiforia's collaboration with Paris Hospital District moves forward

Aiforia Technologies

Translation: Original comment published in Finnish on 9/5/2024 at 12:13 noon EEST.

The start of the collaboration was announced earlier this spring, so the press release comes as no surprise, although the agreement announced now provides a concrete indication of the first steps of the collaboration. According to the release, the collaboration at this stage includes the use of Aiforia's AI solutions in the analysis of tissue samples from prostate cancer patients and the use of Aiforia's AI model development software. Aiforia will be deployed at the pathology department of the Bicetre Hospital (AP-HP Paris Saclay University), which has been a pilot site for digital pathology in France since 2018.

The clinical use of Aiforia in Paris will start on a somewhat smaller scale (1/5 of the current CE-marked AI models), so revenue streams from the customer are expected to be slow. The contract partner, Assistance Publique–Hôpitaux de Paris (AP-HP), is a university hospital group with 38 hospitals in the Paris region, serving 8 million patients per year. Thus, the potential for expansion in this hospital group alone is significant. In addition, Aiforia will be able to demonstrate its product capabilities directly at the heart of the digitization of French pathology and is well positioned to take a significant market share in France, making the collaboration strategically valuable in the longer term. Our forecasts have already included this account and require Aiforia to continue to deliver new customer wins and customer deployment progress, so the release has no impact on our forecasts or our view of the company.

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more on company page

Key Estimate Figures29.08.2024

202324e25e
Revenue2.43.45.8
growth-%49.3 %41.2 %71.1 %
EBIT (adj.)-12.9-12.1-11.8
EBIT-% (adj.)-537.1 %-358.4 %-204.4 %
EPS (adj.)-0.50-0.42-0.41
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a...
12 hours ago
by Verneri Pulkkinen
21
Pre-results update. Despite the share price, target €3.80 & Buy Summary: We remain upbeat on Aiforia’s Foundation Engine and its clinical and...
13 hours ago
by Opa
16
It is certainly possible that deals have also been made below the disclosure threshold. I believe there were a few such deals in H1 as well....
19 hours ago
by Jekkku
5
Well, the latest dip is quite clearly due to Faron (and Optomed). Probably the “retail crowd” got spooked, and many interested in these kinds...
19 hours ago
by JusaVaan
2
Faron is quite an extreme example, as its business seems to be a so-called binary case. It either succeeds or fails; there is no middle ground...
19 hours ago
by Puutaheinää
6
Just as @NanoCapKenobi says. Personally, I don’t invest in these still loss-making biotechs with anything other than a multi-year horizon. The...
19 hours ago
by Vino Pino
9
There is a general pessimistic atmosphere as there have been disappointments in the Finnish biotech scene. People no longer trust mere promises...
21 hours ago
by Optimistinen verkkapöksy
17
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.